Debate: When two drugs in the same class are appropriate, we must choose the lowest-acquisition cost option

NICE guidance for the management of Type 2 diabetes (NG28) recommendations state, “If two drugs in the same class are appropriate, choose the option with the lowest acquisition cost” (ref 1).

Changes in local, regional and national guidance for Type 2 diabetes treatment choice within class (medicines optimisation) could support decisions for NHS cost-improvement plans.

But is this the right choice for HCPs, patients and the NHS? Come to the debate organised by Takeda and chaired by Dr Mike Sadler, “When two drugs in the same class are appropriate, we must choose the lowest-acquisition cost option (in Type 2 diabetes)”  and listen to the arguments for and against the motion before casting your vote in what promises to be an engaging and enjoyable interactive session.

Learning outcomes:

  • To consider how choices in prescribing for Type 2 diabetes could support NHS cost improvement plans; determine whether local, regional and national guidance should reflect these choices.

 

  1. Ref: National Institute for Health and Care Excellence, 2017. Type 2 diabetes in adults: management, NG28. Available from https://www.nice.org.uk/guidance/ng28 (last accessed August 2019)

 

Job Code: UK/VIP/1908/0127 (October 2019)

*This session has been organised and funded by Takeda UK Ltd

Tuesday 29 October 2019

10:10 - 10:50

Primary, Community & Specialist Care

MDT Icon Blue

Speakers

Clinical Non-Executive Director, University Hospital Southampton NHS Foundation Trust & DPC2019 Conference Chair
GP Partner & Medical Education & Scottish Lead, North Berwick Health Centre, GPwSI Diabetes, Primary Care Diabetes Society
Dr David Strain
Senior Clinical Lecturer, Diabetes and Vascular Research Centre, University of Exeter Medical School